Luis
Pérez de Llano
Hospital de Galdakao - Usansolo
Galdácano, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Galdakao - Usansolo (7)
2023
-
First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma
Journal of Investigational Allergology and Clinical Immunology
-
Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population
Archivos de Bronconeumologia, Vol. 59, Núm. 12, pp. 842-845
2019
-
A Simple Score for Future Risk Prediction in Patients with Controlled Asthma Who Undergo a Guidelines-Based Step-Down Strategy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1214-1221.e3
-
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2
-
Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
Respiratory Medicine, Vol. 151, pp. 49-54
2016
-
GEMA 4.0 Spanish guidelines of the management of Asthma
Journal of Investigational Allergology and Clinical Immunology
2015
-
Guidelines for severe uncontrolled asthma
Archivos de Bronconeumologia, Vol. 51, Núm. 5, pp. 235-246